Your shopping cart is currently empty

AZ-PFKFB3-67 is a potent and selective PFKFB3 kinase inhibitor with an IC50=11nM for PFKFB3, reduces MCL-1, and inhibits angiogenesis by decreasing lactic acid production and ATP levels in endothelial cells (ECs) in tube-forming assays, and has neuroprotective effects.

| Pack Size | Price | USA Warehouse | Global Warehouse | Quantity |
|---|---|---|---|---|
| 1 mg | $42 | - | In Stock | |
| 5 mg | $98 | - | In Stock | |
| 10 mg | $156 | - | In Stock | |
| 25 mg | $295 | - | In Stock | |
| 50 mg | $437 | - | In Stock | |
| 100 mg | $646 | - | In Stock | |
| 1 mL x 10 mM (in DMSO) | $108 | - | In Stock |
| Description | AZ-PFKFB3-67 is a potent and selective PFKFB3 kinase inhibitor with an IC50=11nM for PFKFB3, reduces MCL-1, and inhibits angiogenesis by decreasing lactic acid production and ATP levels in endothelial cells (ECs) in tube-forming assays, and has neuroprotective effects. |
| Targets&IC50 | PFKFB2:159 nM, PFKFB1:1130 nM, PFKFB3:11 nM, Intracellular F-2,6-BP production:0.281 μM |
| In vitro | AZ-PFKFB3-67 is a highly selective PFKFB3 inhibitor with strong target inhibitory activity, exhibiting IC₅₀ values of 1.13 μM for PFKFB1, 0.159 μM for PFKFB2, and 0.011 μM for PFKFB3. In cellular assays, AZ-PFKFB3-67 inhibits fructose-2,6-bisphosphate (F-2,6-BP) production with an IC₅₀ of 0.281 μM, while having minimal effect on cellular lactate levels (IC₅₀ > 30 μM), indicating a pronounced inhibitory effect on early glycolytic regulation[1]. |
| Synonyms | AZPFKFB3-67, AZ-PFKFB367 |
| Molecular Weight | 455.51 |
| Formula | C26H25N5O3 |
| Cas No. | 1704741-11-6 |
| Smiles | C(#N)C=1C=2C(N(CC=3C(C)=NOC3C)C1)=CC=C(OC4=CC=C(NC(=O)[C@@H]5CCCN5)C=C4)C2 |
| Relative Density. | 1.34 g/cm3 (Predicted) |
| Storage | store at low temperature | Powder: -20°C for 3 years | In solvent: -80°C for 1 year | Shipping with blue ice/Shipping at ambient temperature. | |||||||||||||||||||||||||||||||||||
| Solubility Information | DMSO: 80 mg/mL (175.63 mM), Sonication is recommended. | |||||||||||||||||||||||||||||||||||
| In Vivo Formulation | 10% DMSO+40% PEG300+5% Tween 80+45% Saline: 2 mg/mL (4.39 mM), Sonication is recommended. Please add the solvents sequentially, clarifying the solution as much as possible before adding the next one. Dissolve by heating and/or sonication if necessary. Working solution is recommended to be prepared and used immediately. The formulation provided above is for reference purposes only. In vivo formulations may vary and should be modified based on specific experimental conditions. | |||||||||||||||||||||||||||||||||||
Solution Preparation Table | ||||||||||||||||||||||||||||||||||||
DMSO
| ||||||||||||||||||||||||||||||||||||
Dissolve 2 mg of the compound in 100 μL DMSO
to obtain a stock solution at a concentration of 20 mg/mL . If the required concentration exceeds the compound's known solubility, please contact us for technical support before proceeding.
1) Add 100 μL of the DMSO
stock solution to 400 μL PEG300
and mix thoroughly until the solution becomes clear.
2) Add 50 μL Tween 80 and mix well until fully clarified.
3) Add 450 μL Saline,PBS or ddH2O
and mix thoroughly until a homogeneous solution is obtained.
| Size | Quantity | Unit Price | Amount | Operation |
|---|

Copyright © 2015-2026 TargetMol Chemicals Inc. All Rights Reserved.